Prudential Financial
CRNX icon

Prudential Financial’s Crinetics Pharmaceuticals CRNX Stock Holding History

Prudential Financial’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$556K Buy
15,310
+9,695
+173% +$433K ﹤0.01% 1820
2025
Q4 		$261K Sell
5,615
-6,005
-52% -$267K ﹤0.01% 2017
2025
Q3 		$484K Sell
11,620
-145,895
-93% -$4.66M ﹤0.01% 1968
2025
Q2 		$4.69M Sell
157,515
-85,360
-35% -$2.64M 0.01% 931
2025
Q1 		$8.28M Sell
242,875
-34,495
-12% -$1.29M 0.01% 664
2024
Q4 		$14.2M Buy
277,370
+104,584
+61% +$5.85M 0.02% 488
2024
Q3 		$8.83M Sell
172,786
-12,969
-7% -$669K 0.01% 733
2024
Q2 		$8.32M Buy
185,755
+41,121
+28% +$1.9M 0.01% 722
2024
Q1 		$6.77M Buy
144,634
+7,689
+6% +$301K 0.01% 811
2023
Q4 		$4.87M Buy
136,945
+4,316
+3% +$132K 0.01% 945
2023
Q3 		$3.89M Buy
132,629
+60,864
+85% +$1.25M 0.01% 1004
2023
Q2 		$1.29M Buy
+71,765
New +$1.43M ﹤0.01% 1675

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Prudential Financial's CRNX Position: Q1 2026 in Review

Prudential Financial increased its Crinetics Pharmaceuticals (CRNX) stake by 173% in Q1 2026, buying an estimated $433K and bringing the position to 15,310 shares worth $556K. The position accounts for ﹤0.01% of the portfolio, ranked #1820.

Prudential Financial first reported a position in CRNX in Q2 2023 and has held it in 12 quarters since. The position peaked at $14.2M in Q4 2024. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

  • Prudential Financial held 15,310 shares of Crinetics Pharmaceuticals worth $556K as of Q1 2026.
  • Prudential Financial bought 9,695 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $433K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Prudential Financial's portfolio in Q1 2026, its #1820 holding.
  • Prudential Financial first reported a position in Crinetics Pharmaceuticals in Q2 2023 and has held it in 12 quarters since.
  • Prudential Financial's Crinetics Pharmaceuticals position peaked at $14.2M in Q4 2024.
  • 243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Prudential Financial's 13F filing for Q1 2026, filed 13 May 2026.